Researchers have discovered that the BCG tuberculosis vaccine can retrain immune cells within the aging brain, potentially offering a preventive strategy against Alzheimer's disease. A study published in Communications Medicine found that the vaccine alters how innate immune cells respond in the central nervous system, though the effect appears most promising as an early intervention before cognitive decline begins.

What Is Trained Immunity and How Does It Work?

The study is based on a phenomenon called trained immunity, in which certain vaccines give innate immune cells a long-lasting memory that makes them respond more effectively to multiple threats, not just the specific pathogen they were designed to fight. Unlike antibodies, which recognize specific germs, trained immunity makes the innate immune system more vigilant overall.

Researchers at Massachusetts General Hospital enrolled 23 older adults, roughly half with and half without cerebrospinal fluid biomarkers indicating Alzheimer's disease. Participants received two BCG doses a month apart, and researchers tracked changes in their blood and cerebrospinal fluid over the following year. The team found that monocytes, the predominant immune cells in cerebrospinal fluid, switched on genes linked to a faster, more alert immune response.

"The findings strikingly reveal that trained immunity-like responses can occur within the central nervous system, which is normally shielded from much of the body's immune activity," said Soumen Basak, an immunologist at the National Institute of Immunology in Delhi.

Soumen Basak, Immunologist at the National Institute of Immunology, Delhi

Why Does the Brain's Immune System Fail in Alzheimer's?

As the immune system ages, it enters a state of chronic, low-grade inflammation called inflammaging. In the brain, this is especially damaging. Immune cells that normally clear toxic amyloid-beta, a protein that clumps together to form the plaques characteristic of Alzheimer's disease, become dysfunctional instead, fueling the neuroinflammation that drives the disease.

The BCG vaccine appears to work differently than expected. Rather than boosting overall immunity, which might worsen brain inflammation, it retrains innate immune cells to respond more effectively. Clinicians have long observed that bladder cancer patients treated with BCG have a lower incidence of dementia, suggesting the vaccine's protective effects may extend beyond its original purpose.

How to Understand the Study's Key Findings

• Promising Results in Early-Stage Participants: In people without established Alzheimer's, amyloid levels fell in cerebrospinal fluid and rose in the blood over the year, a pattern consistent with retrained immune cells helping move amyloid out of the brain and into the body.
• Limited Effect in Advanced Disease: In participants with established Alzheimer's, this beneficial change did not occur, likely because the brain's ongoing inflammatory environment and dementia-related cascades overwhelmed the immune system's capacity to respond.
• Calming Effect Across the Blood-Brain Barrier: The vaccine triggered a sustained rise in inflammatory signaling proteins in blood plasma, but across the blood-brain barrier, cerebrospinal fluid changed into a calming, regulatory state with no sign of runaway neuroinflammation.

When researchers reexposed immune cells to BCG itself in the laboratory, they did not respond more strongly than before. However, they did respond more strongly to an unrelated bacterial molecule called lipopolysaccharide, suggesting the vaccine had put cells on general alert rather than teaching them to recognize BCG alone.

Mahesh Chandra Kodali, a neuroscientist and study co-author at Massachusetts General Hospital, explained that measuring immune changes in cerebrospinal fluid is exceptionally challenging. "From a 10-milliliter blood draw, you get about 10 million immune cells. During a lumbar puncture, you get about 10,000," he noted, making the team's findings particularly significant given the small sample size.

What Are the Limitations and Next Steps?

The study had important limitations. With just 23 participants split into two groups, the research was too small to draw firm conclusions about whether BCG actually treats or prevents Alzheimer's. The study also lacked a placebo group, making it impossible to rule out other explanations for the changes observed. Cognitive scores barely moved either way, which is unsurprising given that dementia develops over several years, far longer than the one-year study period.

However, a different Massachusetts General Hospital trial may offer clues to what a longer timeline could reveal. Denise Faustman has followed BCG-vaccinated type 1 diabetes patients for over five years and has recorded early improvements in a key Alzheimer's-linked marker, suggesting the vaccine's effects may take longer than a year to fully manifest.

"This somewhat dents the therapeutic appeal of BCG in Alzheimer's, while supporting its plausible utility as a preventive measure," said Soumen Basak.

Soumen Basak, Immunologist at the National Institute of Immunology, Delhi

The Banner Alzheimer's Institute has submitted a roughly 200-million-dollar grant application to fund a large, randomized trial testing BCG as an Alzheimer's preventive. Modern anti-amyloid drugs are expensive, whereas BCG is cheap and has decades of safety data behind it, making it an attractive candidate for large-scale testing.

Beyond Alzheimer's, the study points to patterns of gene activity inside the brain's own immune cells as a promising new target for future therapies, potentially reaching beyond neurodegenerative diseases driven by inflammation to other conditions involving immune dysfunction.